PHOTO
Amman, Jordan: – Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, has announced that it has recently signed an exclusive licencing agreement with AFT Pharmaceuticals (AFT) for the registration and commercialization of Combogesic® IV, an intravenous, opioid-free pain relief medicine for the short term symptomatic treatment of acute pain in adults and the reduction of fever, in Saudi Arabia, Jordan, and Iraq. It is a patented intravenous formulation of Paracetamol 1000mg + Ibuprofen 300mg solution for infusion.
The new agreement provides Hikma with exclusive rights for the commercialisation of Combogesic® IV in the three countries. A similar agreement has been previously signed with AFT Pharmaceuticals in the US market and the launch of Combogesic® IV in the US market has been announced earlier this month.
Mazen Darwazah, Hikma’s Executive Vice Chairman and President of MENA, said: “Our agreement with AFT Pharmaceuticals for Combogesic® IV – an important alternative for the treatment of acute pain and fever – is an important milestone in delivering on our purpose of putting better health, within reach, every day. As a leading healthcare company in MENA, we continue to expand our pipeline in growing therapeutic areas and are committed to partnerships with global players to expand our portfolio of high-quality medicines to patients in the region.”
-Ends-
About Hikma
Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible. Headquartered in the UK, we are a global company with a local presence across North America, theMENA and Europe.
Source: AETOSWire
Contacts:
- Hikma Pharmaceuticals PLC
- Mona Abdallah
- Senior Director, MENA Communications
- MBAbdallah@Hikma.com